Structure Therapeutics Key Executives
This section highlights Structure Therapeutics's key executives, including their titles and compensation details.
Find Contacts at Structure Therapeutics
(Showing 0 of )
Structure Therapeutics Earnings
This section highlights Structure Therapeutics's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.
$23.74
Stock Price
$453.33M
Market Cap
163
Employees
South San Francisco, CA
Location
Financial Statements
Access annual & quarterly financial statements for Structure Therapeutics, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $- |
| Cost of Revenue | $- | $949.17K | $623.26K | $266.35K | $20.03K |
| Gross Profit | $- | $-949.17K | $-623.26K | $-266.35K | $-20.03K |
| Gross Profit Ratio | 0.00% | - | - | - | - |
| Research and Development Expenses | $108.81M | $70.10M | $36.19M | $29.11K | $12.36K |
| General and Administrative Expenses | $49.41M | $32.67M | $16.37M | $8.59K | $3.54K |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $49.41M | $32.67M | $16.37M | $8.59K | $3.54K |
| Other Expenses | $- | $0 | $- | $- | $- |
| Operating Expenses | $158.23M | $102.78M | $52.56M | $37.70K | $15.91K |
| Cost and Expenses | $- | $102.78M | $52.56M | $37.70K | $15.91K |
| Interest Income | $- | $13.38M | $1.26M | $122 | $168.29K |
| Interest Expense | $- | $13.39M | $- | $122.16K | $- |
| Depreciation and Amortization | $- | $316.00K | $623.26K | $266.35K | $20.03K |
| EBITDA | $-158.23M | $-102.46M | $-52.28M | $-37.62M | $-15.75M |
| EBITDA Ratio | - | - | - | - | - |
| Operating Income | $-158.23M | $-102.78M | $-52.56M | $-37.70K | $-15.91K |
| Operating Income Ratio | - | - | - | - | - |
| Total Other Income Expenses Net | $36.01M | $13.39M | $1.26M | $-122.00K | $168.00K |
| Income Before Tax | $-122.22M | $-89.38M | $-51.30M | $-37.82K | $-15.74K |
| Income Before Tax Ratio | - | - | - | - | - |
| Income Tax Expense | $310.00K | $236.00K | $17.00K | $231 | $138 |
| Net Income | $-122.53M | $-89.62M | $-51.32M | $-38.05K | $-15.88K |
| Net Income Ratio | - | - | - | - | - |
| EPS | $-0.63 | $-0.60 | $-0.36 | $0.00 | $0.00 |
| EPS Diluted | $-0.63 | $-0.60 | $-0.36 | $0.00 | $0.00 |
| Weighted Average Shares Outstanding | 194.30M | 146.93M | 146.35M | 146.35M | 146.35M |
| Weighted Average Shares Outstanding Diluted | 194.30M | 146.93M | 146.35M | 146.35M | 146.35M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $1.33M | $- | $- | $- | $- | $- | $- | $- | $- |
| Cost of Revenue | $- | $- | $231.74K | $658.93K | $280.92K | $351.02K | $160.26K | $153.70K | $147.75K | $- | $154.23K | $152.21K | $131.25K |
| Gross Profit | $- | $- | $-231.74K | $-658.93K | $1.05M | $-351.02K | $-160.26K | $-153.70K | $-147.75K | $- | $-154.23K | $-152.21K | $-131.25K |
| Gross Profit Ratio | - | 0.00% | - | - | 78.88% | - | - | - | - | - | - | - | - |
| Research and Development Expenses | $33.49M | $32.60M | $22.05M | $20.68M | $20.18M | $17.52M | $19.41M | $13.13M | $8.36M | $9.16M | $10.18M | $8.49M | $9.91K |
| General and Administrative Expenses | $13.57M | $13.24M | $11.27M | $11.34M | $10.95M | $8.63M | $6.58M | $6.51M | $4.60M | $3.53M | $3.78M | $4.46M | $3.37K |
| Selling and Marketing Expenses | $- | $- | $- | $- | $-205.62K | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $13.57M | $13.24M | $11.27M | $11.34M | $10.75M | $8.63M | $6.58M | $6.51M | $4.60M | $3.53M | $3.78M | $4.46M | $3.37K |
| Other Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Operating Expenses | $47.06M | $45.84M | $33.32M | $32.02M | $30.93M | $26.14M | $25.99M | $19.65M | $12.96M | $12.69M | $13.96M | $12.95M | $13.27K |
| Cost and Expenses | $47.06M | $45.84M | $33.32M | $32.02M | $31.21M | $26.14M | $25.99M | $19.65M | $12.96M | $12.69M | $13.96M | $12.95M | $13.27K |
| Interest Income | $- | $- | $- | $- | $6.22M | $2.69M | $2.79M | $1.70M | $899.51K | $- | $- | $- | $2 |
| Interest Expense | $- | $- | $- | $6.01M | $9.58M | $2.69M | $2.83M | $- | $- | $- | $- | $69.00K | $1.00K |
| Depreciation and Amortization | $273.00K | $265.00K | $232.00K | $658.93K | $280.92K | $351.02K | $160.26K | $153.70K | $147.75K | $76.00K | $154.23K | $152.21K | $131.25K |
| EBITDA | $-46.79M | $-45.57M | $-33.08M | $-31.79M | $-30.91M | $-26.14M | $-25.91M | $-19.58M | $-12.88M | $-12.62M | $-13.90M | $-12.88M | $-13.17M |
| EBITDA Ratio | - | - | - | - | -2323.74% | - | - | - | - | - | - | - | - |
| Operating Income | $-47.06M | $-45.84M | $-33.32M | $-32.02M | $-31.21M | $-26.14M | $-25.99M | $-19.65M | $-12.96M | $-12.69M | $-13.96M | $-12.95M | $-13.27K |
| Operating Income Ratio | - | - | - | - | -2346.46% | - | - | - | - | - | - | - | - |
| Total Other Income Expenses Net | $10.72M | $11.95M | $7.33M | $6.01M | $6.18M | $2.69M | $2.83M | $1.70M | $901.00K | $349.00K | $76.00K | $-69.00K | $-1.00K |
| Income Before Tax | $-36.34M | $-33.88M | $-25.98M | $-26.01M | $-24.99M | $-23.46M | $-23.16M | $-17.95M | $-12.05M | $-12.34M | $-13.88M | $-13.02M | $-13.28K |
| Income Before Tax Ratio | - | - | - | - | -1878.67% | - | - | - | - | - | - | - | - |
| Income Tax Expense | $136.00K | $92.00K | $53.00K | $29.00K | $-314.14K | $405.00K | $118.00K | $25.00K | $-180.00K | $73.00K | $64.00K | $60.00K | $81 |
| Net Income | $-36.48M | $-33.98M | $-26.03M | $-26.04M | $-24.67M | $-23.86M | $-23.28M | $-17.98M | $-11.88M | $-13.93M | $-13.95M | $-13.08M | $-15.43K |
| Net Income Ratio | - | - | - | - | -1855.04% | - | - | - | - | - | - | - | - |
| EPS | $-0.19 | $-0.17 | $-0.13 | $-0.14 | $-0.13 | $-0.16 | $-0.15 | $-0.12 | $-0.08 | $-0.14 | $-0.14 | $-0.13 | $0.00 |
| EPS Diluted | $-0.19 | $-0.17 | $-0.13 | $-0.14 | $-0.13 | $-0.16 | $-0.15 | $-0.12 | $-0.08 | $-0.14 | $-0.14 | $-0.13 | $0.00 |
| Weighted Average Shares Outstanding | 190.96M | 197.65M | 197.65M | 186.28M | 185.63M | 153.26M | 153.01M | 149.68M | 146.35M | 101.93M | 101.93M | 101.93M | 101.93M |
| Weighted Average Shares Outstanding Diluted | 190.96M | 197.65M | 197.65M | 186.28M | 185.63M | 153.26M | 153.01M | 149.68M | 146.35M | 101.93M | 101.93M | 101.93M | 101.93M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $169.51M | $129.79M | $90.84M | $105.31K | $16.35K |
| Short Term Investments | $714.01M | $337.53M | $64.75M | $2.00K | $21.09K |
| Cash and Short Term Investments | $883.52M | $467.32M | $90.84M | $107.31K | $37.45K |
| Net Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Other Current Assets | $7.69M | $6.29M | $2.25M | $1.94M | $974.00K |
| Total Current Assets | $891.21M | $473.61M | $93.09M | $109.25K | $38.42K |
| Property Plant Equipment Net | $7.01M | $8.36M | $1.29M | $1.79K | $277 |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $5.11M | $45.00K | $3.46M | $111 | $8 |
| Total Non-Current Assets | $12.12M | $8.41M | $4.76M | $1.91K | $285 |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $903.33M | $482.02M | $97.84M | $111.16K | $38.70K |
| Account Payables | $8.02M | $4.74M | $6.01M | $3.48M | $1.53M |
| Short Term Debt | $1.70M | $1.44M | $520.00K | $349.00K | $147.00K |
| Tax Payables | $- | $356.00K | $174.00K | $231 | $138 |
| Deferred Revenue | $- | $- | $- | $- | $- |
| Other Current Liabilities | $26.30M | $18.20M | $6.31M | $-3.82M | $-1.67M |
| Total Current Liabilities | $36.02M | $24.74M | $13.01M | $8.66K | $3.04K |
| Long Term Debt | $2.16M | $4.01M | $- | $272.00K | $133.00K |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $302.00K | $298.00K | $- | $-104.77K | $-74.87K |
| Total Non-Current Liabilities | $2.47M | $4.31M | $199.97M | $167.23K | $58.13K |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $38.49M | $29.05M | $212.99M | $175.89K | $61.17K |
| Preferred Stock | $- | $- | $133.01M | $166.96M | $58.00M |
| Common Stock | $17.00K | $14.00K | $1.00K | $1 | $1 |
| Retained Earnings | $-329.10M | $-206.57M | $-116.95M | $-64.74K | $-22.95K |
| Accumulated Other Comprehensive Income Loss | $914.00K | $521.00K | $-110.00K | $-166.96M | $-1 |
| Other Total Stockholders Equity | $1.19B | $659.00M | $1.92M | $1,000 | $-57.52M |
| Total Stockholders Equity | $864.84M | $452.97M | $-115.14M | $-64.73K | $-22.47K |
| Total Equity | $864.84M | $452.97M | $-115.14M | $-64.73K | $-22.47K |
| Total Liabilities and Stockholders Equity | $903.33M | $482.02M | $97.84M | $111.16K | $38.70K |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $903.33M | $482.02M | $97.84M | $111.16K | $38.70K |
| Total Investments | $714.01M | $337.53M | $64.75M | $2.00K | $21.09K |
| Total Debt | $3.86M | $5.45M | $260.00K | $621 | $280 |
| Net Debt | $-165.65M | $-124.34M | $-90.58M | $-104.68K | $-16.07K |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | March 31, 2022 | December 31, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $169.51M | $172.13M | $381.63M | $97.83M | $129.79M | $50.64M | $40.59M | $126.49M | $26.09M | $28.09M | $-107.31M | $105.31K |
| Short Term Investments | $714.01M | $743.16M | $545.49M | $338.61M | $337.53M | $154.79M | $184.00M | $114.37M | $64.75M | $74.66M | $214.61M | $2.00K |
| Cash and Short Term Investments | $883.52M | $915.29M | $927.12M | $436.44M | $467.32M | $205.42M | $224.59M | $240.86M | $90.84M | $102.75M | $107.31M | $107.31K |
| Net Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Assets | $7.69M | $8.37M | $10.50M | $12.91M | $6.29M | $4.54M | $3.63M | $5.29M | $2.25M | $2.02M | $- | $1.94M |
| Total Current Assets | $891.21M | $923.65M | $937.62M | $449.36M | $473.61M | $209.96M | $228.22M | $246.16M | $93.09M | $104.77M | $107.31M | $109.25K |
| Property Plant Equipment Net | $7.01M | $7.74M | $7.58M | $7.82M | $8.36M | $6.06M | $1.17M | $1.14M | $1.29M | $1.37M | $- | $1.79K |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-74.58M | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $5.11M | $1.82M | $1.83M | $47.00K | $45.00K | $350.00K | $38.00K | $59.00K | $3.46M | $76.85M | $-107.31M | $111 |
| Total Non-Current Assets | $12.12M | $9.57M | $9.41M | $7.86M | $8.41M | $6.41M | $1.21M | $1.20M | $4.76M | $3.64M | $-107.31M | $1.91K |
| Other Assets | $- | $- | $- | $- | $1 | $- | $- | $- | $- | $-0 | $- | $- |
| Total Assets | $903.33M | $933.22M | $947.03M | $457.22M | $482.02M | $216.37M | $229.43M | $247.35M | $97.84M | $108.41M | $- | $111.16K |
| Account Payables | $8.02M | $8.45M | $2.21M | $6.54M | $4.74M | $3.32M | $5.70M | $4.95M | $6.01M | $5.70M | $- | $3.48M |
| Short Term Debt | $1.70M | $1.71M | $1.63M | $1.60M | $2.88M | $817.00K | $73.00K | $168.00K | $520.00K | $330.00K | $- | $349.00K |
| Tax Payables | $- | $139.00K | $41.00K | $297.00K | $356.00K | $580.00K | $176.00K | $104.00K | $174.00K | $147.00K | $- | $231 |
| Deferred Revenue | $- | $- | $- | $297.00K | $356.00K | $- | $- | $- | $- | $- | $- | $-3.48M |
| Other Current Liabilities | $26.30M | $23.14M | $18.78M | $15.15M | $16.76M | $15.38M | $9.06M | $5.79M | $6.31M | $6.05M | $- | $-3.82M |
| Total Current Liabilities | $36.02M | $33.43M | $22.66M | $23.59M | $24.74M | $20.09M | $15.01M | $11.00M | $13.01M | $12.23M | $- | $8.66K |
| Long Term Debt | $2.16M | $2.67M | $3.04M | $3.52M | $4.01M | $3.03M | $- | $- | $- | $- | $- | $272.00K |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $302.00K | $309.00K | $293.00K | $295.96K | $298.00K | $281.00K | $- | $- | $- | $200.09M | $- | $-104.77K |
| Total Non-Current Liabilities | $2.47M | $2.98M | $3.34M | $3.82M | $4.31M | $3.31M | $1.00K | $5.11M | $199.97M | $200.09M | $- | $167.23K |
| Other Liabilities | $- | $- | $- | $1 | $1 | $- | $- | $-5.11M | $- | $- | $- | $- |
| Total Liabilities | $38.49M | $36.42M | $26.00M | $27.41M | $29.05M | $23.41M | $15.01M | $11.00M | $212.99M | $212.32M | $- | $175.89K |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $133.01M | $199.97K | $166.96M | $166.96M |
| Common Stock | $17.00K | $17.00K | $17.00K | $14.00K | $14.00K | $11.00K | $10.00K | $11.00K | $1.00K | $1.00K | $- | $1 |
| Retained Earnings | $-329.10M | $-292.62M | $-258.64M | $-232.61M | $-206.57M | $-182.07M | $-158.21M | $-134.93M | $-116.95M | $-105.08M | $- | $-64.74K |
| Accumulated Other Comprehensive Income Loss | $914.00K | $2.84M | $-487.00K | $-90.00K | $521.00K | $-310.00K | $-390.00K | $147.00K | $-110.00K | $-135.00K | $-64.73M | $-166.96M |
| Other Total Stockholders Equity | $1.19B | $1.19B | $1.18B | $662.50M | $659.00M | $375.33M | $373.00M | $371.12M | $1.92M | $1.10M | $- | $1,000 |
| Total Stockholders Equity | $864.84M | $896.80M | $921.03M | $429.81M | $452.97M | $192.96M | $214.41M | $236.35M | $-115.14M | $-103.91M | $102.22M | $-64.73K |
| Total Equity | $864.84M | $896.80M | $921.03M | $429.81M | $452.97M | $192.96M | $214.41M | $236.35M | $-115.14M | $-103.91M | $102.22M | $-64.73K |
| Total Liabilities and Stockholders Equity | $903.33M | $933.22M | $947.03M | $457.22M | $482.02M | $216.37M | $229.43M | $247.35M | $97.84M | $108.41M | $102.22M | $111.16K |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $903.33M | $933.22M | $947.03M | $457.22M | $482.02M | $216.37M | $229.43M | $247.35M | $97.84M | $108.41M | $102.22M | $111.16K |
| Total Investments | $714.01M | $743.16M | $545.49M | $338.61M | $337.53M | $154.79M | $184.00M | $114.37M | $64.75M | $74.66K | $214.61M | $2.00K |
| Total Debt | $3.86M | $4.38M | $4.67M | $5.12M | $5.45M | $3.85M | $73.00K | $168.00K | $260.00K | $330.00K | $- | $621 |
| Net Debt | $-165.65M | $-167.75M | $-376.95M | $-92.71M | $-124.34M | $-46.78M | $-40.52M | $-126.33M | $-25.83M | $-27.76M | $107.31M | $-104.68K |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-122.53M | $-89.62M | $-51.32M | $-38.05K | $-15.88K |
| Depreciation and Amortization | $992.00K | $295.00K | $277.00K | $72 | $20.03K |
| Deferred Income Tax | $- | $- | $- | $27 | $-20.03K |
| Stock Based Compensation | $18.79M | $8.19M | $2.51M | $1.49M | $570.00K |
| Change in Working Capital | $2.96M | $6.97M | $2.97M | $4.06K | $946 |
| Accounts Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Accounts Payables | $3.31M | $-859.25K | $2.15M | $1.90K | $1.02K |
| Other Working Capital | $-343.00K | $7.83M | $815.00K | $2.17K | $-74 |
| Other Non Cash Items | $-16.86M | $-5.32M | $-558.00K | $241 | $77 |
| Net Cash Provided by Operating Activities | $-116.64M | $-79.49M | $-46.12M | $-32.16K | $-14.28K |
| Investments in Property Plant and Equipment | $-1.29M | $-2.17M | $-155.00K | $-1.21K | $-19 |
| Acquisitions Net | $- | $- | $61.95K | $-19.07K | $- |
| Purchases of Investments | $-702.52M | $-416.99M | $-123.45M | $-4.21K | $-21.13K |
| Sales Maturities of Investments | $344.90M | $151.05M | $61.50M | $23.28K | $- |
| Other Investing Activities | $- | $-231.38K | $-61.95K | $19.07K | $-21.13K |
| Net Cash Used for Investing Activities | $-358.91M | $-268.34M | $-62.11M | $17.86K | $-21.15K |
| Debt Repayment | $- | $- | $- | $- | $- |
| Common Stock Issued | $514.57M | $472.30M | $- | $103.39M | $25.88M |
| Common Stock Repurchased | $- | $- | $-6.00K | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $690.00K | $-20.77M | $29.02M | $103.25K | $25.84M |
| Net Cash Used Provided by Financing Activities | $515.26M | $451.53M | $29.01M | $103.25K | $25.84K |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $39.72M | $103.70M | $-79.21M | $88.95K | $-9.59K |
| Cash at End of Period | $169.51M | $129.79M | $26.09M | $105.31K | $16.35K |
| Cash at Beginning of Period | $129.79M | $26.09M | $105.31M | $16.35K | $25.95K |
| Operating Cash Flow | $-116.64M | $-79.49M | $-46.12M | $-32.16K | $-14.28K |
| Capital Expenditure | $-1.29M | $-2.17M | $-155.00K | $-1.21K | $-19 |
| Free Cash Flow | $-117.93M | $-81.66M | $-46.27M | $-33.37K | $-14.30K |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-36.48M | $-33.98M | $-26.03M | $-25.99M | $-24.67M | $-23.86M | $-23.28M | $-17.98M | $-11.88M | $-12.42M | $-13.95M | $-13.08M | $-13.36K |
| Depreciation and Amortization | $273.00K | $265.00K | $231.74K | $658.93K | $280.92K | $79.00K | $74.00K | $70.00K | $72.00K | $76.00K | $59.00K | $70.00K | $66 |
| Deferred Income Tax | $- | $- | $- | $- | $-1.27M | $-1.66M | $-1.64M | $- | $410.00K | $-280.00K | $-130.00K | $6.01K | $4 |
| Stock Based Compensation | $5.83M | $6.02M | $4.20M | $2.74M | $2.10M | $1.86M | $1.70M | $2.53M | $623.00K | $628.00K | $643.00K | $620.00K | $937 |
| Change in Working Capital | $-534.00K | $10.19M | $-2.03M | $-8.16M | $2.73M | $2.75M | $6.17M | $-4.67M | $-444.00K | $1.42M | $3.19M | $-1.19M | $1.52K |
| Accounts Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $-423.00K | $6.30M | $-4.38M | $1.82M | $1.39M | $-2.38M | $1.04M | $-923.00K | $-124.00K | $2.27M | $1.57M | $-1.56M | $1.09K |
| Other Working Capital | $-111.00K | $3.89M | $2.35M | $-9.97M | $1.34M | $5.13M | $5.12M | $-3.75M | $-320.00K | $-846.00K | $1.61M | $371.00K | $439 |
| Other Non Cash Items | $-5.56M | $-2.20M | $-2.75M | $-1.03M | $-1.08M | $276.00K | $88.00K | $-262.00K | $-812.00K | $93.00K | $96.00K | $65.00K | $65 |
| Net Cash Provided by Operating Activities | $-36.47M | $-19.70M | $-26.39M | $-34.02M | $-21.91M | $-20.56M | $-16.89M | $-20.31M | $-12.03M | $-10.48M | $-10.10M | $-13.52M | $-10.76K |
| Investments in Property Plant and Equipment | $-16.00K | $-685.26K | $-427.00K | $-161.74K | $-1.16M | $-820.00K | $-191.00K | $- | $-71.00K | $-72.00K | $53.00K | $-65.00K | $-120 |
| Acquisitions Net | $- | $- | $- | $- | $-37.57K | $-30.95K | $68.52K | $- | $-10.41K | $16.59K | $16.13K | $- | $- |
| Purchases of Investments | $-132.25M | $-255.18M | $-283.22M | $-31.87M | $-237.01M | $-14.93M | $24.26M | $-190.10M | $-9.19M | $-45.98M | $-26.63M | $-41.65M | $- |
| Sales Maturities of Investments | $165.50M | $66.55M | $79.40M | $33.45M | $57.28M | $45.88M | $-92.78M | $141.08M | $19.60M | $29.40M | $10.50M | $2.00M | $1.20K |
| Other Investing Activities | $- | $275.07K | $-275.06K | $1.58K | $-1 | $30.95K | $-68.52K | $-49.02K | $10.41K | $-16.59K | $-16.13K | $-39.65K | $1.20K |
| Net Cash Used for Investing Activities | $33.23M | $-189.04M | $-204.51M | $1.42M | $-180.89M | $30.13M | $-68.71M | $-49.02M | $10.34M | $-16.66M | $-16.07M | $-39.72M | $1.08K |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $-515.33M | $514.57M | $753.77K | $300.00M | $775.82K | $-534.05K | $172.30M | $- | $- | $31.46M | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-5.99K | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $615.00K | $-757.00K | $-562.39K | $702.00K | $-18.37M | $473.00K | $-297.00K | $-2.57M | $-316.00K | $-259.00K | $31.04M | $-1.45M | $-115.00K |
| Net Cash Used Provided by Financing Activities | $615.00K | $-757.00K | $514.01M | $700.86K | $281.97M | $473.00K | $-297.00K | $169.73M | $-316.00K | $-259.00K | $31.04M | $-1.45M | $-115 |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $-15.69K | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $-2.62M | $-209.50M | $283.81M | $-31.96M | $79.16M | $10.04M | $-85.90M | $100.40M | $-2.00M | $-27.40M | $4.87M | $-54.68M | $-9.79K |
| Cash at End of Period | $169.51M | $172.13M | $381.64M | $97.83M | $129.79M | $50.64M | $40.59M | $126.49M | $26.09M | $28.09M | $55.49M | $50.62M | $105.31K |
| Cash at Beginning of Period | $172.13M | $381.63M | $97.83M | $129.79M | $50.64M | $40.59M | $126.49M | $26.09M | $28.09M | $55.49M | $50.62M | $105.31M | $115.10K |
| Operating Cash Flow | $-36.47M | $-19.70M | $-26.39M | $-34.02M | $-21.91M | $-20.56M | $-16.89M | $-20.31M | $-12.03M | $-10.48M | $-10.10M | $-13.52M | $-10.76K |
| Capital Expenditure | $-16.00K | $-685.00K | $-427.00K | $-161.74K | $-1.16M | $-820.00K | $-191.00K | $- | $-71.00K | $-72.00K | $53.00K | $-65.00K | $-120 |
| Free Cash Flow | $-36.48M | $-20.38M | $-26.82M | $-34.19M | $-23.07M | $-21.38M | $-17.09M | $-20.31M | $-12.10M | $-10.55M | $-10.04M | $-13.58M | $-10.88K |
Structure Therapeutics Dividends
Explore Structure Therapeutics's dividend history, including dividend yield, payout ratio, and historical payments.
Structure Therapeutics News
Read the latest news about Structure Therapeutics, including recent articles, headlines, and updates.
Structure: A Lot Riding On Next Data Readout For Oral GLP-1 Candidate
Structure Therapeutics' stock has declined over 40% since last year, but its differentiated technology platform and promising drug pipeline still support a "Buy" rating. Structure's lead candidate, aleniglipron, an oral GLP-1R agonist, shows potential in obesity treatment with significant Phase 2 data expected in Q4 2025. Despite a crowded GLP-1 drug development field, Structure's oral small molecule approach and strong financial position offer a competitive edge.
Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences
SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced that management will participate in multiple upcoming healthcare conferences being held in February and March.
Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity
Preclinical studies with ACCG-2671 demonstrate potent target engagement, robust weight loss, favorable safety profile and PK properties supportive of once-daily dosing in humans
Structure Therapeutics to Participate in the Jefferies London Healthcare Conference
SAN FRANCISCO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced that management will participate in a presentation and fireside chat, and host one-on-one meetings at the Jefferies London Healthcare Conference being held November 19-21, 2024, in London, UK.
Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity
Phase 2b ACCESS study designed to evaluate multiple doses up to 120 mg of GSBR-1290 over 36 weeks Comprehensive development program also includes Phase 2 ACCESS II study to evaluate even higher doses of GSBR-1290 over 36 weeks; first patient expected to be dosed by end of 2024 Topline data from both ACCESS and ACCESS II studies expected in the fourth quarter of 2025 Company to host conference call today at 4:30 p.m. Eastern Time SAN FRANCISCO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced the first patients have been dosed in the randomized, double-blind, placebo-controlled Phase 2b ACCESS clinical study evaluating GSBR-1290 in participants living with obesity, or overweight with a weight-related comorbidity.
Nxera Pharma and Antiverse Enter Collaboration To Design Novel GPCR-Targeted Antibody Therapeutics Using Generative AI
Tokyo, Japan and London and Cardiff, UK, 5 November 2024 – Nxera Pharma (“Nxera”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – and Antiverse, a techbio company designing antibodies for challenging targets, have today announced a multi-target partnership and licensing agreement to design antibodies for G-protein coupled receptors (GPCRs).
Structure Therapeutics: Potential To Have Best-In-Class GLP-1 Agonist For Obesity Patients
Positive 12-week data from phase 2a study of GSBR-1290 targeting obesity patients; significant placebo adjusted mean weight loss of 6.2% & 6.9% achieved for capsule and tablet respectively. One analyst believes that the market for obesity treatments could expand to $200 billion by 2031. The 36-week phase 2b study, using GSBR-1290 for the treatment of patients with obesity, expected to start in Q4 of 2024.
Does Structure Therapeutics Inc. Sponsored ADR (GPCR) Have the Potential to Rally 115.8% as Wall Street Analysts Expect?
The consensus price target hints at an 115.8% upside potential for Structure Therapeutics Inc. Sponsored ADR (GPCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D.
SAN FRANCISCO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced key leadership appointments to drive its next phase of development and operational success. Blai Coll, M.D., Ph.D., has been promoted to Chief Medical Officer, replacing Mark Bach, M.D., Ph.D. as part of a planned succession, effective September 18. Dr. Coll has served as Vice President of Clinical Development at Structure since 2022, leading the GSBR-1290 program, Structure's oral small molecule GLP-1 agonist that is planned to enter Phase 2b clinical development for obesity in the fourth quarter of 2024. In addition, Ashley Hall, J.D., has been appointed to the newly created position of Chief Development Officer, and will be responsible for clinical development operations, project management, regulatory affairs and quality assurance.
Structure Therapeutics Appoints Angus C. Russell to Board of Directors
Former Shire CEO brings more than 30 years of experience in building and scaling companies in the global biopharmaceutical industry Former Shire CEO brings more than 30 years of experience in building and scaling companies in the global biopharmaceutical industry
Structure Therapeutics Announces Participation in Upcoming Investor Conferences
SAN FRANCISCO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced management will participate at the following investor conferences in September:
Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say
While Eli Lilly & Co. and Novo Nordisk dominate the obesity-drug market, there's a vast field of would-be competitors closing in behind them — and the most successful among those next-wave contenders stand to capture up to 20% of the lucrative market, Jefferies analysts said in a research note Monday.
Structure Therapeutics Stock Could Rocket 87% Higher, According to 1 Wall Street Analyst. Is It Time to Buy?
Structure Therapeutics is a clinical-stage biotech developing a small-molecule drug that mimics an important gut hormone. Early results for Structure Therapeutics' lead candidate compare well with Wegovy and experimental weight management treatments.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for GPCR.